Welcome to our dedicated page for Kymera Therapeutics news (Ticker: KYMR), a resource for investors and traders seeking the latest updates and insights on Kymera Therapeutics stock.
Kymera Therapeutics, Inc. (NASDAQ: KYMR) is a biotechnology company harnessing the power of targeted protein degradation (TPD) to develop transformative treatments for previously untreatable diseases. Founded in 2016, and headquartered in Watertown, Massachusetts, Kymera is at the forefront of biotechnology, utilizing the body's innate protein recycling machinery to degrade disease-causing proteins rather than merely inhibiting them.
The company's pioneering platform, Pegasus™, leverages proprietary predictive modeling and an integrated degradation approach to address disease targets previously deemed intractable. This novel modality allows Kymera to target and degrade proteins involved in various critical pathways, including those in immunological diseases and oncology. Key drugs in their pipeline include:
- KT-474: An IRAK4 degrader currently in Phase 2 trials for immuno-inflammatory conditions.
- KT-333: A STAT3 degrader in Phase 1 trials, targeting hematological malignancies and solid tumors.
- KT-253: An MDM2 degrader undergoing Phase 1 trials, aimed at cancers with p53 pathway involvement.
- KT-621: A STAT6 degrader poised to enter Phase 1 trials, showing promising preclinical results for treating TH2-driven diseases like asthma and atopic dermatitis.
Kymera's achievements include successful partnerships with leading pharmaceutical companies such as Sanofi, ongoing collaborations with research institutions, and securing significant financial backing with over $745 million in cash reserves to support operations into 2027. The company's innovative approach and robust pipeline have earned it recognition as one of Boston’s top workplaces.
Kymera continues to make significant strides in drug discovery and development, with a focus on delivering highly effective, convenient oral therapies. Recent updates include positive preclinical and clinical data presentations at major medical conferences, highlighting the potential of their degradation technology to revolutionize treatment paradigms across various diseases.
For more information, visit Kymera Therapeutics or follow them on X (formerly Twitter) and LinkedIn.
Kymera Therapeutics (NASDAQ: KYMR) has announced the selection of a late-breaking abstract for presentation at the SID 2021 Annual Meeting from May 3-8, 2021. The abstract features new patient data related to hidradenitis suppurativa (HS) from a non-interventional study assessing IRAK4 expression and the effects of the IRAK4 degrader, KT-474. Presentation details include the title: Multiple mediators of inflammation correlate with IRAK4 expression in HS patients, scheduled for May 6, 2021, from 2:30 PM-4:00 PM ET.
Kymera Therapeutics (NASDAQ: KYMR) has appointed Elena Ridloff, CFA, to its Board of Directors, effective March 16, 2021. Ridloff will serve as Chair of the Audit Committee and brings over 20 years of biopharmaceutical experience, having held senior roles at commercial-stage firms and as an institutional investor. Kymera aims to leverage her expertise to advance its targeted protein degradation platform, focusing on innovative therapies for challenging diseases. Ridloff expressed excitement to contribute to Kymera's transformative year, as the company progresses three novel protein degrader programs into the clinic.
Kymera Therapeutics (NASDAQ: KYMR) announced significant advancements in its drug development pipeline, including the first-in-human dosing of KT-474, an oral IRAK4 degrader for immune-inflammatory diseases. The company also declared KT-333 as a development candidate for tumor treatments. Financially, collaboration revenues surged to $12.8 million in Q4 2020, up from $1.8 million in Q4 2019, while net losses increased to $12.7 million from $11.5 million year-over-year. With $458.7 million in cash, Kymera is well-positioned to fund operations through 2025.
Kymera Therapeutics has initiated dosing in a Phase 1 clinical trial for KT-474, the first IRAK4 degrader outside oncology, targeting immune-inflammatory diseases like atopic dermatitis and hidradenitis suppurativa. This trial marks a significant milestone for the company and the targeted protein degradation field. The trial aims to assess the safety, tolerability, and pharmacokinetics in both healthy volunteers and patients. With plans for future oncology trials, the company is optimistic about KT-474's potential to outperform current treatments.
Kymera Therapeutics (NASDAQ: KYMR) announced its participation in several upcoming investor conferences. Key events include:
- Cowen 41st Annual Health Care Conference on March 3 at 11:40 a.m. ET.
- H.C. Wainwright Global Life Sciences Conference available on-demand from March 9 at 7:00 a.m. ET.
- Guggenheim Targeted Protein Degradation Day on March 16 at 10:30 a.m. ET.
- Morgan Stanley Virtual Healthcare Corporate Access Day on March 16.
Webcasts will be accessible on the company's website for around 30 days post-event.
Kymera Therapeutics (NASDAQ: KYMR) has announced its participation in two investor conferences. The conferences include the Guggenheim Healthcare Talks 2021 Oncology Day on February 11 at 1:30 p.m. ET and the BMO BioPharma Spotlight Series on February 18 at 10:30 a.m. ET. Both events will feature live webcasts available on the company’s website, with archived replays accessible for approximately 90 days. Kymera focuses on targeted protein degradation, offering innovative solutions for immune-inflammatory diseases and cancers through its Pegasus™ platform.
Kymera Therapeutics (NASDAQ: KYMR) announced key leadership changes on February 3, 2021, appointing Ashwin Gollerkeri, MD, as Senior VP of Development and Kevin Dushney as VP of Information Technology. Karen Martin has been promoted to VP, Head of Legal. The company aims to advance its targeted protein degradation approach and plans to progress three novel protein degrader programs into clinical development this year, targeting diseases including immune-inflammatory conditions and cancer. The team’s combined expertise is expected to enhance Kymera's capabilities in drug development.
Kymera Therapeutics (NASDAQ: KYMR) announced its 2021 pipeline objectives, marking a pivotal year as it transitions into a clinical-stage company. The company plans to initiate Phase 1 trials for three novel degrader programs, focusing on immune-inflammatory diseases and oncology. The first clinical trial for KT-474 is expected to start in 1Q 2021, while the company has a strong financial position with approximately $458 million in cash to support its operations through 2025. Additionally, it aims to advance its Pegasus™ platform for targeted protein degradation to develop transformative therapies.
Kymera Therapeutics (NASDAQ: KYMR) announced its participation in the virtual 39th Annual J.P. Morgan Healthcare Conference scheduled for January 14, 2021. Nello Mainolfi, Co-Founder and CEO, will discuss the company’s advancements and expected milestones for 2021 at 2:00 p.m. ET. A live webcast will be available on the company’s website, with an archived version accessible for 90 days. Kymera focuses on targeted protein degradation to treat immune-inflammatory diseases and cancers, utilizing its Pegasus™ platform to harness the body’s natural processes.
Kymera Therapeutics (NASDAQ: KYMR) has appointed William Leong, PhD, as Vice President of Chemistry, Manufacturing and Controls (CMC), and Paul Cox as Vice President of Investor Relations and Communications. These strategic hires are expected to bolster the company’s operational capabilities as it approaches clinical development. Leong brings over 30 years of drug development experience, while Cox has 15 years in investor relations. Kymera aims to advance targeted protein degradation therapies to address complex disease targets using its proprietary Pegasus™ platform.
FAQ
What is the current stock price of Kymera Therapeutics (KYMR)?
What is the market cap of Kymera Therapeutics (KYMR)?
What is Kymera Therapeutics' main focus?
What is the Pegasus platform?
What are some key drugs in Kymera's pipeline?
What diseases is Kymera targeting?
What recent achievements has Kymera made?
How does Kymera's technology differ from conventional therapies?
Who are Kymera's partners?
Where is Kymera Therapeutics headquartered?
How is Kymera funded?
Where can I find more information about Kymera?
